综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

USEUROPEAFRICAASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Foreign interest grows in aging society

By LIU JIE | China Daily | Updated: 2013-03-30 01:56

Foreign interest grows in aging society

World headquarters of Pfizer Inc in New York.Provided to China Daily

Liu Zhanglin has been working in China's pharmaceutical industry — especially the consumer healthcare and traditional Chinese medicine segments — for nearly three decades.

The industry veteran forecasts the nation's consumer healthcare sector will grow at a steady 10 percent over the next three to five years.

Bruce Liu, a strategy consultant with equally rich experience in the international pharmaceutical industry, is even more optimistic.

He suggests that by 2015, the sector will be worth more than 100 billion yuan ($16.01 billion) from its current 60 billion yuan, and will be growing at around 20 percent annually.

But both professionals share one view — that the sector is likely to become one of China's most lucrative.

Liu Zhanglin, vice-president of China Chamber of Commerce for Import & Export of Medicines & Health Products, is slightly more conservative with his growth forecasts, but predicts the sector will accelerate at a higher rate than the nation's GDP growth, given the country's aging population.

Bruce Liu, a partner and co-head of the pharma and healthcare practice at Roland Berger Strategy Consultants, said one of the most striking aspects of China's fast-growing consumer healthcare sector is the number of multinational pharmaceutical companies competing in an attempt to cash in on market.

Pfizer Inc, the world's largest drugmaker by sales, for instance, announced at the end of January that it planned to target the China healthcare market with launch of a new supplement series.

"Pronutrients" is an advanced line of Pfizer's famous multivitamin brand "Centrum" and has been promoted to China only after its launch in the home market, the United States.

Pfizer now has several mature supplement brands in China, another being "Caltrate".

Related Readings

'Best time' to invest in healthcare industry

Healthcare reform improves equal access

Looking abroad for healthcare

China becoming healthcare R&D hub

Previous Page 1 2 3 4 5 Next Page

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
讷河市| 三明市| 军事| 安溪县| 邵阳市| 阳信县| 惠东县| 从化市| 甘南县| 额敏县| 石屏县| 十堰市| 揭东县| 新乡市| 治县。| 左云县| 梁河县| 海盐县| 吴江市| 项城市| 郸城县| 澎湖县| 巩义市| 甘孜| 大厂| 呼和浩特市| 垫江县| 华蓥市| 策勒县| 前郭尔| 武功县| 当阳市| 万州区| 垫江县| 新丰县| 通江县| 报价| 塔城市| 叶城县| 威信县| 合作市|